+ Filter
Loading...
Custom Services order now ship next day

DDR1

Loading...

Anti-DDR1 Products

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs is dedicated to accelerating the research and discovery of the target DDR1 by providing high-quality, cutting-edge recombinant antibodies designed against DDR1. Our antibodies are developed using advanced technologies to ensure optimal specificity and reliability for various applications in biomedical research. We understand the significance of DDR1 in numerous physiological processes and disease mechanisms, and our mission is to equip researchers with the tools they need to explore this critical target. By choosing our products, you gain a trusted partner in advancing your scientific inquiries and discoveries.

DDR1: A Crucial Target in Inflammatory Disorders and Cancer

The target Discoidin Domain Receptor 1 (DDR1) is a receptor tyrosine kinase. DDR1 plays a crucial role in various biological processes including cell adhesion, migration, proliferation, and extracellular matrix remodeling. Research on DDR1 is significant as it helps understand the mechanisms underlying these processes and their roles in development and disease. Targeting DDR1 may offer potential therapeutic strategies for diseases such as cancer, fibrosis, and inflammatory disorders. Additionally, understanding DDR1 may provide insights into the development of novel diagnostic tools and drug targets.

Alternative Names

Discoidin domain receptor tyrosine kinase 1; CAK; CD167; DDR; EDDR1; HGK2; MCK10; NEP; NTRK4; PTK3; PTK3A; RTK6; TRKE

Background

Receptor tyrosine kinases play a key role in the communication of cells with their microenvironment. These kinases are involved in the regulation of cell growth, differentiation and metabolism. The protein encoded by this gene belongs to a subfamily of tyrosine kinase receptors with homology to Dictyostelium discoideum protein discoidin I in their extracellular domain, and that are activated by various types of collagens. Expression of this protein is restricted to epithelial cells, particularly in the kidney, lung, gastrointestinal tract, and brain. In addition, it is significantly overexpressed in several human tumors. Alternatively, spliced transcript variants encoding different isoforms have been described for this gene.

Anti-DDR1 rAb Products

We supply high-quality and superior antibody products to meet the research requirements of a broad spectrum of researchers regarding target DDR1 and its functions.

Creative Quality Control

To meet the diverse demands of our customers, we have taken deliberate steps. During the production process of antibody products, we have established a series of rigorous quality management systems. This is done to ensure that every product is of high quality and meets the expectations of our customers.

Fig.1 SDS-PAGE analysis of TAB-176MZ. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-DDR1 antibody
(Cat# TAB-176MZ, Creative Biolabs).

Fig.2 SEC-HPLC analysis of TAB-176MZ. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-DDR1 antibody
(Cat# TAB-176MZ, Creative Biolabs).

Fig.3 ELISA analysis of TAB-176MZ. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-DDR1 antibody
(Cat# TAB-176MZ, Creative Biolabs).

Fig.4 WB analysis of TAB-176MZ. (Creative Biolabs Original)Fig.4 WB analysis of anti-DDR1 antibody
(Cat# TAB-176MZ, Creative Biolabs).

Customer Reviews

Excellent
H**ly
Anti-Human DDR1 Recombinant Antibody (DDR1-ab1) (Cat#: TAB-176MZ)
I used the anti-human DDR1 recombinant antibody in my research. I employed it in an immunofluorescence assay to detect DDR1 expression in certain tumor cells. The results were remarkable. The antibody showed high specificity and sensitivity, clearly highlighting the presence of DDR1 and aiding in my understanding of its role in tumor progression.
17/Mar/2022
Excellent
J**ie
Mouse Anti-DDR1 Recombinant Antibody (clone mAb 3E3) (Cat#: PABL-436)
As a customer, I utilized the mouse anti-DDR1 recombinant antibody for my research. In my experiments, this antibody was used to detect the presence of DDR1 in specific tissues. When tested with ELISA and flow cytometry, it demonstrated excellent specificity and sensitivity, yielding accurate and dependable results that helped me better understand DDR1's function in those tissues.
27/Oct/2022

rAb Production

We offer extensive one-stop services that encompass everything from gene synthesis to the production of high-quality recombinant antibodies. This comprehensive approach enables us to meet diverse customer needs. Thanks to this, we are thoroughly capable of providing customers with excellent antibody production services.

Featured Anti-DDR1 Recombinant Antibody Production PlatformsFig.5 Milligram-scale anti-DDR1 recombinant antibody production. (Creative Biolabs Original)
Fig.5 Milligram-scale recombinant antibody production.

Fig.6 Gram-scale anti-DDR1 recombinant antibody production. (Creative Biolabs Original)Fig.6 Gram-scale recombinant antibody production.

rAb Modalities

We are firmly committed to providing researchers with an extremely extensive selection and cutting-edge high-quality recombinant antibodies in a diverse range of formats. This enables researchers to conduct their studies more effectively and contribute to the advancement of scientific research.

Fig.7 Full Length Anti-DDR1 Recombinant Antibody Production and Modalities. (Creative Biolabs Original)Fig.7 Full Length Anti-DDR1 Recombinant Antibody Production and Modalities.

Drug Information Targeting DDR1

Table 1. Therapeutic approaches targeting DDR1 in clinical development.

Research phase Company Classification Indications Details
Launched - 2007 Dana-Farber Cancer Institute Small Molecules Acute lymphocytic leukemia;
Cancer
This is a signal transduction inhibitor that selectively inhibits the tyrosine kinase Bcr-Abl.
Launched - 2006 Bristol-Myers Squibb Small Molecules Acute lymphocytic leukemia;
Acute myeloid leukemia;
Cancer
It is a highly potent, small-molecule Src kinase and Bcr-Abl kinase inhibitor developed at Bristol-Myers Squibb, was launched in the U.S. in 2006 for the treatment of chronic myelogenous leukemia (CML) in chronic, accelerated or blast phase and for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (ALL).
Pre-Registered Handa Pharmaceuticals Small Molecules Chronic myeloid leukemia;
Lymphocytic leukemia
It is being developed at Handa Pharmaceutical using its ONCORE(TM) technology for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company filed an application seeking approval in the U.S. in 2022. However, the FDA issued a complete response letter in 2023.
Phase II Aurigene Small Molecules Cancer This is a VEGF and FGFR inhibitor, that is in phase II clinical development at Aurigene for the treatment of advanced solid tumors. Previously originator Orion (FI) completed phase I clinical trials for the same indication.
Phase II Lilly Small Molecules Cancer It is a human growth factor receptor (HGFR) inhibitor with an antiangiogenic activity that also inhibits receptor tyrosine oncokinases including FLT3, AXL, ROS1, and DDR1/2.

For further information about our anti-DDR1 recombinant antibody products, please don't hesitate to reach out to us at any time. Our knowledgeable team is here to assist you with any inquiries you may have, and we are eager to provide the support you need for your research.

Go to compare

Go to compare